Distinct cDC subsets co-operate in CD40 agonist response while suppressive microenvironments and lack of antigens subvert efficacy
Murgaski, A.; Kiss, M.; Van Damme, H.; Kancheva, D.; Vanmeerbeek, I.; Keirsse, J.; Hadadi, E.; Brughmans, J.; Arnouk, S. M.; Hamouda, A. E. I.; Debraekeleer, A.; Bosteels, V.; Elkrim, Y.; Boon, L.; Hoves, S.; Vandamme, N.; Deschoemaeker, S.; Janssens, S.; Garg, A. D.; Schmittnaegel, M.; Ries, C. H.; Laoui, D.
Show abstract
Agonistic CD40 therapy has shown to inhibit cancer progression, but only in a fraction of patients. Hence, understanding the cancer cell-intrinsic and microenvironmental determinants of CD40 therapy response is crucial to identify responsive patient populations and design efficient combination treatments. Here, we showed that the therapeutic efficacy of CD40 in responder melanoma tumours, relied on pre-existing cDC1-primed CD8+ T cells, however cDC1s were dispensable after CD40 administration. Surprisingly, in response to CD40 the abundance of activated cDCs, potentially derived from cDC2s increased, thereby further activating antitumour CD8+ T cells. Hence, distinct cDC subsets are required to induce CD40 responses. By contrast, lung tumours, characterised by a high abundance of macrophages, were resistant to CD40 therapy. Combining CD40 therapy with macrophage depletion led to tumour growth inhibition only in the presence of strong neoantigens. Accordingly, treatment with immunogenic cell-death inducing chemotherapy sensitised non-immunogenic tumours to CD40 therapy.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Combined PARP14 Inhibition and PD-1 Blockade Promotes Cytotoxic T Cell Quiescence and Modulates Macrophage Polarisation in Relapsed Melanoma 97%
- Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling. 97%
- MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer 96%
Similar papers in this journal
- IFNgamma-dependent remodelling of the myeloid landscape underlies control of IFNgamma-insensitive tumours 97%
- Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold tumours hot 96%
- Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers 96%
Similar papers in this journal
- Inflammasome- and gasdermin D-independent IL-1β production mobilizes neutrophils to inhibit antitumor immunity 97%
- The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed/Refractory Diffuse Large B Cell Lymphoma 97%
- Targeting macrophages with CAR-T cells delays solid tumor progression and enhances anti-tumor immunity 96%
Similar papers in this journal
- Functionally and metabolically divergent melanoma-associated macrophages originate from common bone-marrow precursors 97%
- Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model 96%
- Early neutrophilia marked by aerobic glycolysis sustains host metabolism and delays cancer cachexia 95%
Similar papers in this journal
- CRISPR/Cas9 screen identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer 97%
- A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma 95%
- Lymphatic PD-L1 expression restricts tumor-specific CD8+ T cell responses 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.